CHRNB3 c.-57A>G functional promoter change affects Parkinson's disease and smoking

Neurobiology of Aging

Volumn 35, Issue 9, 2014, Pages 2179.e1-2179.e6

  Bar Shira, Anat ^a,c   Gana Weisz, Mali ^a,c   Gan Or, Ziv ^a,b,c   Giladi, Eytan ^a,b   Giladi, Nir ^a,b   Orr Urtreger, Avi ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

CHRNB3; Genetics; Parkinson's disease; Smoking; 3 nicotinic acetylcholine receptor subunit

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 1; CHRNB3 PROTEIN, HUMAN; NICOTINE; NICOTINIC RECEPTOR;

ADULT; ARTICLE; BINDING AFFINITY; CHRNB3 GENE; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; INTRON; LYMPHOBLAST; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POPULATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SMOKING; AGED; CORPUS STRIATUM; DEFICIENCY; GENETIC ASSOCIATION; GENETICS; HETEROZYGOTE; METABOLISM; MIDDLE AGED;

AGED; CORPUS STRIATUM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; NICOTINE; OCTAMER TRANSCRIPTION FACTOR-1; PARKINSON DISEASE; PROMOTER REGIONS, GENETIC; RECEPTORS, NICOTINIC; SMOKING;

EID: 84902076855     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.03.014     Document Type: Article

References (36)

1. Albuquerque E.X., Pereira E.F., Alkondon M., Rogers S.W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 2009, 89:73-120.
2. Bar-Shira A., Matarasso N., Rosner S., Bercovich D., Matzkin H., Orr-Urtreger A. Mutation screening and association study of the candidate prostate cancer susceptibility genes MSR1, PTEN, and KLF6. Prostate 2006, 66:1052-1060.
3. Champtiaux N., Gotti C., Cordero-Erausquin M., David D.J., Przybylski C., Lena C., Clementi F., Moretti M., Rossi F.M., Le Novere N., McIntosh J.M., Gardier A.M., Changeux J.P. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J.Neurosci. 2003, 23:7820-7829.
4. Chen H., Huang X., Guo X., Mailman R.B., Park Y., Kamel F., Umbach D.M., Xu Q., Hollenbeck A., Schatzkin A., Blair A. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010, 74:878-884.
5. Cui C., Booker T.K., Allen R.S., Grady S.R., Whiteaker P., Marks M.J., Salminen O., Tritto T., Butt C.M., Allen W.R., Stitzel J.A., McIntosh J.M., Boulter J., Collins A.C., Heinemann S.F. The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. J.Neurosci. 2003, 23:11045-11053.
6. Do C.B., Tung J.Y., Dorfman E., Kiefer A.K., Drabant E.M., Francke U., Mountain J.L., Goldman S.M., Tanner C.M., Langston J.W., Wojcicki A., Eriksson N. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet. 2011, 7:e1002141.
7. Ehringer M.A., McQueen M.B., Hoft N.R., Saccone N.L., Stitzel J.A., Wang J.C., Bierut L.J. Association of CHRN genes with "dizziness" to tobacco. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:600-609.
8. Gan-Or Z., Bar-Shira A., Dahary D., Mirelman A., Kedmi M., Gurevich T., Giladi N., Orr-Urtreger A. Association of sequence alterations in the putative promoter of RAB7L1 with a reduced Parkinson disease risk. Arch. Neurol. 2012, 69:105-110.
9. Gan-Or Z., Bar-Shira A., Gurevich T., Giladi N., Orr-Urtreger A. Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease. Neurogenetics 2011, 12:325-332.
10. Gan-Or Z., Giladi N., Rozovski U., Shifrin C., Rosner S., Gurevich T., Bar-Shira A., Orr-Urtreger A. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008, 70:2277-2283.
11. Gotti C., Zoli M., Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci. 2006, 27:482-491.
12. Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron 2010, 68:201-206.
13. Hernan M.A., Takkouche B., Caamano-Isorna F., Gestal-Otero J.J. Ameta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 2002, 52:276-284.
14. Hoft N.R., Corley R.P., McQueen M.B., Schlaepfer I.R., Huizinga D., Ehringer M.A. Genetic association of the CHRNA6 and CHRNB3 genes with tobacco dependence in a nationally representative sample. Neuropsychopharmacology 2009, 34:698-706.
15. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J.Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
16. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M., Simon-Sanchez J., Schulte C., Lesage S., Sveinbjornsdottir S., Stefansson K., Martinez M., Hardy J., Heutink P., Brice A., Gasser T., Singleton A.B., Wood N.W. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649. International Parkinson Disease Genomics, C.
17. Kaiser S.A., Soliakov L., Harvey S.C., Luetje C.W., Wonnacott S. Differential inhibition by alpha-conotoxin-MII of the nicotinic stimulation of [3H]dopamine release from rat striatal synaptosomes and slices. J.Neurochem. 1998, 70:1069-1076.
18. Kas A., Bottlaender M., Gallezot J.D., Vidailhet M., Villafane G., Gregoire M.C., Coulon C., Valette H., Dolle F., Ribeiro M.J., Hantraye P., Remy P. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J.Cereb. Blood Flow Metab. 2009, 29:1601-1608.
19. Keller M.F., Saad M., Bras J., Bettella F., Nicolaou N., Simon-Sanchez J., Mittag F., Buchel F., Sharma M., Gibbs J.R., Schulte C., Moskvina V., Durr A., Holmans P., Kilarski L.L., Guerreiro R., Hernandez D.G., Brice A., Ylikotila P., Stefansson H., Majamaa K., Morris H.R., Williams N., Gasser T., Heutink P., Wood N.W., Hardy J., Martinez M., Singleton A.B., Nalls M.A. Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum. Mol. Genet. 2012, 21:4996-5009. International Parkinson's Disease Genomics, C., Wellcome Trust Case Control, CWellcome Trust Case Control, C.
20. Kelton M.C., Kahn H.J., Conrath C.L., Newhouse P.A. The effects of nicotine on Parkinson's disease. Brain Cogn. 2000, 43:274-282.
21. Lill C.M., Roehr J.T., McQueen M.B., Kavvoura F.K., Bagade S., Schjeide B.M., Schjeide L.M., Meissner E., Zauft U., Allen N.C., Liu T., Schilling M., Anderson K.J., Beecham G., Berg D., Biernacka J.M., Brice A., DeStefano A.L., Do C.B., Eriksson N., Factor S.A., Farrer M.J., Foroud T., Gasser T., Hamza T., Hardy J.A., Heutink P., Hill-Burns E.M., Klein C., Latourelle J.C., Maraganore D.M., Martin E.R., Martinez M., Myers R.H., Nalls M.A., Pankratz N., Payami H., Satake W., Scott W.K., Sharma M., Singleton A.B., Stefansson K., Toda T., Tung J.Y., Vance J., Wood N.W., Zabetian C.P., Young P., Tanzi R.E., Khoury M.J., Zipp F., Lehrach H., Ioannidis J.P., Bertram L. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet. 2012, 8:e1002548. 23andMe Genetic Epidemiology of Parkinson's Disease, C., International Parkinson's Disease Genomics, C.International Parkinson's Disease Genomics, C., Parkinson's Disease, G.C.Parkinson's Disease, G.C., Wellcome Trust Case Control, C.Wellcome Trust Case Control, C.
22. Lindstrom J.M. Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. Ann. N. Y. Acad. Sci. 2003, 998:41-52.
23. Mitsuoka T., Kaseda Y., Yamashita H., Kohriyama T., Kawakami H., Nakamura S., Yamamura Y. Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism. Hiroshima J. Med. Sci. 2002, 51:33-39.
24. Obeso J.A., Rodriguez-Oroz M.C., Goetz C.G., Marin C., Kordower J.H., Rodriguez M., Hirsch E.C., Farrer M., Schapira A.H., Halliday G. Missing pieces in the Parkinson's disease puzzle. Nat. Med. 2010, 16:653-661.
25. Pankratz N., Beecham G.W., DeStefano A.L., Dawson T.M., Doheny K.F., Factor S.A., Hamza T.H., Hung A.Y., Hyman B.T., Ivinson A.J., Krainc D., Latourelle J.C., Clark L.N., Marder K., Martin E.R., Mayeux R., Ross O.A., Scherzer C.R., Simon D.K., Tanner C., Vance J.M., Wszolek Z.K., Zabetian C.P., Myers R.H., Payami H., Scott W.K., Foroud T., Consortium P.G. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann. Neurol. 2012, 71:370-384.
26. Parkinson Study G. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology 2006, 66:408-410.
27. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 2004, 27:561-568.
28. Quik M., O'Leary K., Tanner C.M. Nicotine and Parkinson's disease: implications for therapy. Mov. Disord. 2008, 23:1641-1652.
29. Saccone N.L., Schwantes-An T.H., Wang J.C., Grucza R.A., Breslau N., Hatsukami D., Johnson E.O., Rice J.P., Goate A.M., Bierut L.J. Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans. Genes Brain Behav. 2010, 9:741-750.
30. Saccone S.F., Hinrichs A.L., Saccone N.L., Chase G.A., Konvicka K., Madden P.A., Breslau N., Johnson E.O., Hatsukami D., Pomerleau O., Swan G.E., Goate A.M., Rutter J., Bertelsen S., Fox L., Fugman D., Martin N.G., Montgomery G.W., Wang J.C., Ballinger D.G., Rice J.P., Bierut L.J. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 2007, 16:36-49.
31. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., Kawaguchi T., Tsunoda T., Watanabe M., Takeda A., Tomiyama H., Nakashima K., Hasegawa K., Obata F., Yoshikawa T., Kawakami H., Sakoda S., Yamamoto M., Hattori N., Murata M., Nakamura Y., Toda T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41:1303-1307.
32. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Kruger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
33. Thorgeirsson T.E., Gudbjartsson D.F., Surakka I., Vink J.M., Amin N., Geller F., Sulem P., Rafnar T., Esko T., Walter S., Gieger C., Rawal R., Mangino M., Prokopenko I., Magi R., Keskitalo K., Gudjonsdottir I.H., Gretarsdottir S., Stefansson H., Thompson J.R., Aulchenko Y.S., Nelis M., Aben K.K., den Heijer M., Dirksen A., Ashraf H., Soranzo N., Valdes A.M., Steves C., Uitterlinden A.G., Hofman A., Tonjes A., Kovacs P., Hottenga J.J., Willemsen G., Vogelzangs N., Doring A., Dahmen N., Nitz B., Pergadia M.L., Saez B., De Diego V., Lezcano V., Garcia-Prats M.D., Ripatti S., Perola M., Kettunen J., Hartikainen A.L., Pouta A., Laitinen J., Isohanni M., Huei-Yi S., Allen M., Krestyaninova M., Hall A.S., Jones G.T., van Rij A.M., Mueller T., Dieplinger B., Haltmayer M., Jonsson S., Matthiasson S.E., Oskarsson H., Tyrfingsson T., Kiemeney L.A., Mayordomo J.I., Lindholt J.S., Pedersen J.H., Franklin W.A., Wolf H., Montgomery G.W., Heath A.C., Martin N.G., Madden P.A., Giegling I., Rujescu D., Jarvelin M.R., Salomaa V., Stumvoll M., Spector T.D., Wichmann H.E., Metspalu A., Samani N.J., Penninx B.W., Oostra B.A., Boomsma D.I., Tiemeier H., van Duijn C.M., Kaprio J., Gulcher J.R., Consortium E., McCarthy M.I., Peltonen L., Thorsteinsdottir U., Stefansson K. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet. 2010, 42:448-453.
34. Wei J., Chu C., Wang Y., Yang Y., Wang Q., Li T., Zhang L., Ma X. Association study of 45 candidate genes in nicotine dependence in Han Chinese. Addict. Behav. 2012, 37:622-626.
35. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 2011, 26(Suppl. 1):S1-S58.
36. Zoli M., Moretti M., Zanardi A., McIntosh J.M., Clementi F., Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J.Neurosci. 2002, 22:8785-8789.